Immune-Based Antitumor Effects of BRAF Inhibitors Rely on Signaling by CD40L and IFNγ

Melanoma is considered a highly aggressive form of cancer and its resistance to chemotherapy results in high-mortality rates (1, 2). More than 50% of melanomas contain the V600E mutation in the B-Raf kinase gene (Braf^V600E), which causes constitutive activation of B-Raf and the downstream mitogen-activated protein kinase (MAPK) pathway that contributes to malignancy by increasing cellular glycolysis, anabolic metabolism, proliferation, and suppressing apoptosis (1, 3, 4). Selective inhibitors targeting the oncogenic Braf^V600E, but not wild-type B-Raf kinase, have been shown to trigger apoptosis and reduce proliferation in melanoma cell lines in in vitro cell culture and in vivo animal models. Importantly, treatment of patients with metastatic melanoma harboring Braf^V600E mutation with the oral Braf inhibitors, vemurafenib and dabrafenib, prevents tumor progression in a high frequency of patients and in some cases induces tumor regression, and vemurafenib improves overall survival compared with chemotherapy (1, 4, 5). Despite the initial therapeutic benefits of vemurafenib, resistance to treatment inevitably occurs within a few months and this progressive form of melanoma seems intractable to current therapies (4). Multiple mechanisms, including additional mutations in RAS kinase and other proteins in the MAPK pathway, are involved in developing resistance to Braf^V600E inhibitors (4).

Tumors are infiltrated by several types of immune cells, including T lymphocytes, natural killer cells, and macrophages that have the potential to kill tumor cells or curb their growth via production of cytotoxic molecules, chemokines, and inflammatory cytokines (6, 7). However, their antitumor functions are commonly suppressed by other immunoregulatory immune cells, such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSC, categorized by CD11b⁺/Gr-1⁺ surface staining), alternative activated macrophages (often referred to as M2-like macrophages), and immature or tolerogenic dendritic cells that also accumulate within the tumor microenvironment (8). In addition to blocking antitumor immune responses, these immunomodulatory cells can also promote tumor growth and metastasis through secretion of angiogenic factors (e.g., VEGF). Intratumoral T cells also upregulate inhibitory receptors, such as PD1, TIM3, CTLA4, and LAG3, which further repress antitumor effector functions upon ligand binding in the tumor microenvironment (9, 10). Importantly, recent clinical trials have found that blocking CTLA4 and PD1 signaling with monoclonal antibodies can evoke preexisting antitumor immunity and cause partial or, in some cases, complete tumor regression in a fraction of patients (11, 12). In contrast to the negative signaling pathways controlled by PD1 and CTLA4, CD40:CD40L signaling and costimulatory ligands, including CD70 and CD86, have been suggested to provide positive signals that boost antitumor immunity (13–16). These studies demonstrate the potential power of immunotherapy in treating cancer, but the issue remains that a large number of patients are unresponsive to these immunotherapies for reasons that are not entirely clear.

The Braf^V600E mutation has a direct role in driving cellular transformation, but multiple studies suggest that it also indirectly modulates the tumor microenvironment. For instance, tumors treated with Braf^V600E inhibitors displayed increased T lymphocyte infiltration and expression of melanoma antigens, MHCI, and PDL1 expression (17–21). Similarly, mice engrafted with a melanoma cell line and treated with the vemurafenib analogue PLX4720 also demonstrated increased T-cell infiltration in tumors and responsiveness to antigens (18, 22). The antitumor effects of PLX4720 in this engraftment model was particularly dependent on CD8 T cells and could be enhanced by CD137 agonistic mAb treatment, suggesting that Braf^V600E inhibitors can sensitize tumors to certain immunotherapies (22). In contrast, another study concluded that PLX4720 decreased T-cell infiltration in the tumors and were unable to enhance antitumor responses in conjunction with CTLA4 blockade (23). Thus, more investigation is needed to better characterize the nature of the tumor microenvironment in melanoma and how Braf^V600E inhibitors affect the function of infiltrating immune cells. Elucidating signals that create a more immunostimulatory tumor microenvironment by Braf^V600E inhibitors could offer mechanistic insight into drug action and potentially identify new drug targets for improving anticancer therapies.

This study focused on the effects of PLX4720 on antitumor immunity in an inducible murine melanoma model that provides a highly physiologically relevant setting for studying the complex interplay between tumor, stromal, and immune cells in the tumor microenvironment. We found that as tumors grew the tumor microenvironment gradually acquired immunosuppressive features, including accumulation of Tregs and CD11b⁺/Gr-1⁺ myeloid cells and reduced effector functions of tumor-infiltrating CD4 T cells. Importantly, PLX4720-stimulated host antitumor immune responses that inhibited tumor progression through CD40L- and IFNγ-dependent mechanisms. Interestingly, blockade of CD40:CD40L or IFNγ signaling differentially affected the immunoregulatory cells in the tumor microenvironment, suggesting these signaling pathways operate in a nonoverlapping manner. We also demonstrated that agonistic anti-CD40 antibody treatment alone was effective to inhibit tumor growth in this model. These findings reveal that host immunity is a critical component of B-Raf^V600E inhibitor-mediated tumor suppression and provide new immunotherapeutic targets, such as CD40 and IFNγ, for enhancing antimelanoma immunity that could be used in conjunction with B-Raf^V600E inhibitors or other immunotherapies.

The BRaf^CA; Tyr::CreER; Pten^lox4-5 (Braf/Pten) mice were previously described (3) and Pmel TCR transgenic mice were purchased from Jackson laboratory (24). For local tumor induction, 3-week-old Braf/Pten mice were administrated with 1 μL 4-hydroxytamoxifen (4-HT; 8 mg/mL in ethanol) topically on the back skin and examined every week for melanoma growth. All animal experiments were performed according to the approved protocols of Institutional Animal Care and Use Committee.

Tumors were minced in digestion media (Hank's Balanced Salt Solution with 0.5 mg/mL collagenase IV and 200 μg/mL DNase), incubated at 37°C for 1 hour and filtered to remove undigested tumor pieces. Single-cell suspensions were then incubated with 2-mL ACK lysis buffer (Invitrogen), washed and resuspended in complete RPMI.

Single-cell suspensions from tumors or splenocytes were incubated with anti-Fc receptor antibody (2.4G2) on ice for 15 minutes in FACS buffer (PBS with 1% FBS and sodium azide). The cells were then stained with the appropriate antibodies in 2.4G2-containing FACS buffer on ice for 30 minutes. For intracellular cytokine staining, T cells were stimulated with phorbol 12—myristate 13—acetate (PMA)/ionomycin (Sigma Aldrich) and Brefeldin A for 5 hours, stained with surface antibodies and then fixed in Cytofix/Cytoperm buffer (BD Biosciences) or transcription factor staining buffer (ebioscience) and stained with antibodies to detect intracellular cytokines or FoxP3, respectively. All samples were acquired on LSRII flow cytometer and analyzed Flowjo. Cell sorting was performed on BD FACS Aria in Yale Cell Sorter Core Facility. Tumor-infiltrating dendritic cells (TIDC) were sorted based on the following markers: CD45⁺/CD3⁻/CD11c⁺/Gr-1⁻. TAMs were sorted based on the following markers: CD45⁺/CD3⁻/CD11b⁺/Gr-1⁻/F4/80⁺. Antibodies against CD45 (A20), CD8 (53-6.7), CD3 (145-2C11), CD44 (IM7), CD11c (N418), CD11b (M1/70), Gr-1 (RB6-8C5), IFNγ (XMG1.2), IL2 (JES6-5H4), TNFα (TN3-19), FoxP3 (FJK-16s), MHCII (M5/114.15.2), and CD70 (FR70) were purchased from eBioscience. Antibodies against CD4 (RM4-5), F4/80 (BM8), CD40L (MR1), MHCI (KH95), CD80 (16-10A1), and CD40 (3/23) were from Biolegend and anti-CD86 (GL1) was from BD Biosciences.

Five weeks after tumor induction, tumor-bearing Braf^V600E/Pten mice were fed with normal or PLX4720-containing chow (417 mg PLX4720/kg; generously provided by Plexxikon) for another 21 days. Tumor weight and tumor-infiltrating immune cells were assessed following treatments. In some cases, the Braf/Pten mice (either on normal or PLX4720-containing chow) were administered anti-CD40L (MR1) or -IFNγ (XMG1.2; 250 μg/mouse i.p.) or control vehicle (PBS) every 3 days from weeks 5 to 7. Alternatively, Braf/Pten mice were treated with control IgG or agonistic anti-CD40 antibody (FGK45; 250 μg/mouse) every 3 days from weeks 6 to 8. Tumor growth was determined by measuring the tumor height with a caliper every 3 days and at the end of treatment, tumors were resected and tumor weight and immune response were determined.

Splenic cells of Pmel TCR transgenic mice were collected and CD8⁺ Pmel T cells were enriched by negative CD8 T-Cell Enrichment Kit (Stemcell Technologies). Naïve CD8⁺ Pmel T cells were further purified by removing CD44⁺ cells with Biotin Selection Kit (Stemcell Technologies). Purified naïve Pmel cells were then loaded with 2 μmol/L CFSE at room temperature for 15 minutes. CFSE-labeled naïve CD8⁺ Pmel T cells were mixed with TIDCs in a 5:1 ratio in the presence of 1 μg/mL gp100. For agonistic anti-CD40 antibody, the cell mixtures were incubated with 50 μg/mL of IgG (Bioxcell) or agonistic anti-CD40 antibody (FGK45; Bioxcell) during this period. Proliferation of CD8⁺ Pmel T cells was determined by FACS analysis to measure CFSE dilution.

For RNA purification, TRIzol (Invitrogen) reagent was used to extract total RNA according to manufacturer's instruction and cDNAs were synthesized using SuperScript II Reverse Transcriptase (Invitrogen). Quantitative real-time PCR was performed on Mx3000P qPCR System (Agilent Technologies) with iTaq Universal SYBR Green Supermix (Bio-Rad). Primer sequences to indicated mRNAs were listed in Supplementary Table. Ct values were measured and relative gene expression was calculated using ΔΔCt method.

Data were presented in means ± SD. Statistical analysis was performed by unpaired Student t test and P value < 0.05 was considered as statistically significant.

We first examined the immune cell infiltrate in melanomas in the Tyr-creER^T2/Braf^V600E/Pten^lox mice. In this system, application of 4-HT to the skin initiates melanoma formation by introducing constitutively active form of B-Raf kinase (Braf^V600E) and Pten deletion in melanocytes (3, 25). It takes approximately 8 weeks for these tumors to grow to a size more than 200 mm² and mice usually die within 10 weeks after tumor induction (3). To examine if there were any changes in the tumor microenvironment associated with tumor progression, we collected tumor samples from mice at early stages (5 weeks) and advanced stages (8 weeks) after 4-HT induction and examined multiple properties of the intratumoral immune cells using flow cytometry (Fig. 1A). Several notable observations were made during this longitudinal study. First, the frequency of tumor-infiltrating CD4⁺ and CD8⁺ T lymphocytes increased as tumors progressed and CD4⁺ T cells were the dominant T-cell population in this model (Fig. 1B). In addition, we found that the frequency of CD11b⁺/Gr-1⁺ cells (commonly referred to as MDSCs) increased, but the populations of TIDCs (CD45⁺/CD11c⁺/Gr-1⁻) and tumor-associated macrophages (TAM) (CD45⁺/CD11b⁺/F4/80⁺/Gr-1⁻) decreased as the tumor grew (Fig. 1B). Gating criteria for above myeloid cell populations are shown in Supplementary Fig. S1; note ∼40% of TIDC expressed F4/80 as reported previously (26). We also determined the frequency of FoxP3⁺ Tregs among tumor-infiltrating CD4 T cells and found that FoxP3⁺ Tregs accumulated in the tumors over time (Fig. 1C). Importantly, the frequency of FoxP3⁺ Tregs in the spleen of tumor-bearing animals did not change over this time period, indicating that the increase in intratumoral Tregs was unique to the tumor microenvironment and not because of systemic increases in Tregs in the animals.

The increase in two immunosuppressive cell types, CD11b⁺/Gr-1⁺ cells and Tregs, in Braf^V600E/Pten melanomas prompted us to assess the effector functions of tumor-infiltrating T lymphocytes. We did not detect statistically significant changes in effector cytokine production in tumor-infiltrating CD8 T cells (Supplementary Fig. S2). However, the percentage of IFNγ, TNFα, and IL2-producing CD4 T cells decreased as tumors grew (Fig. 1D). Intriguingly, the loss of cytokine production between early and advanced tumor stages also correlated with a decrease in expression of the costimulatory ligand CD40L on the FoxP3⁻ (non-Treg) CD4 T cells (Fig. 1E). Taken together, these results showed that as Braf^V600E/Pten melanomas grew, the tumor microenvironment acquired multiple immunosuppressive features wherein Tregs and MDSCs accumulated, and critical CD4 T-cell helper and effector functions decayed. These changes might lead to ineffective antitumor immune responses and the establishment of a protumorigenic microenvironment.

CD40:CD40L signaling is a critical licensing mechanism that enhances maturation of dendritic cells and macrophages and helps boost CD8 T-cell activation and expansion under less-inflammatory conditions (27, 28). In macrophages, CD40:CD40L signaling promotes the development of classically activated (M1)-like macrophages that produce IL12 to help T_H1 differentiation and reactive oxygen species (ROS) and nitric oxide (NO) to eliminate pathogens or cancer cells (13, 28–30). In contrast, tumors typically contain alternatively activated (M2)-like macrophages that produce IL10, VEGF, and matrix metalloproteinases (MMP) that assist type-2 immune responses and/or dampen immune responses to promote wound healing (31). Although a variety of mechanisms can regulate macrophage skewing from M1 → M2-like states in tumors, it has not been well explored if this involves changes in CD40:CD40L signaling within the tumor microenvironment (8, 32, 33). Because the expression of CD40L declined on CD4 T cells as Braf^V600E/Pten melanomas progressed, we postulated that the maturation or activation status of TIDCs and TAMs might also be affected. Interestingly, in early-stage tumors (5 weeks), we observed relatively high amounts of MHC class I and II and costimulatory ligands (CD70, CD80, and CD86) expression on both TIDCs and TAMs. However, the expression of these proteins declined substantially in the advanced stage tumors present at 8 weeks (Fig. 2A).

We next probed the macrophages for M1- and M2-like markers during tumor progression, and found that the expression of M1-like cytokines Il1β, Il6, and Il12 declined whereas the expression of Tnfα and M2-like genes, including Arg1, Chi3l3, Mr1, and Mmp9, increased (Fig. 2B). This result indicated more M2-like macrophages resided in late-stage tumors. Moreover, TIDCs isolated from advanced Braf^V600E/Pten melanomas lost their capacity to stimulate gp100-specific (Pmel) CD8 T-cell proliferation as compare to TIDCs isolated from early stage of tumors (Fig. 2C). Taken together, these results showed a gradual loss of mature antigen-presenting cells (APC), but an accumulation of M2-like macrophages as Braf^V600E/Pten melanomas grew. To test whether APCs in advanced Braf^V600E/Pten melanomas were responsive or nonresponsive to CD40:CD40L signaling, we incubated the TAMs and TIDCs purified from advanced Braf^V600E/Pten melanomas with control IgG or agonistic anti-CD40 antibody (FGK45) overnight. Indeed, TAMs were responsive to CD40:CD40L signaling and M1-like gene expression was upregulated more profoundly than M2-like gene expression (Fig. 2D). In addition, FGK45 mAb enhanced the ability of the advanced staged TIDCs to stimulate naïve Pmel CD8 T cell activation and proliferation (Fig. 2E). These data suggest that TIDCs and TAMs in advanced Braf^V600E/Pten melanomas had developed tolerogenic features commonly associated with tumors such as reduced expression of MHC and costimulatory ligands and that the TAMs had undergone an M1 → M2-like phenotypic switch. However, both TIDCs and TAMs of advanced staged melanoma were sensitive to CD40:CD40L signaling, suggesting a model whereby as the tumors grow, the loss of CD4 T cell CD40L expression may contribute to the decline in APC maturation and thus, T-cell activity.

Although host immunity has been implicated in the antitumor effects of Braf^V600E inhibitors in melanoma, it is not clear which immune signaling pathways are most affected by Braf^V600E inhibitors and how these pathways alter the tumor microenvironment and antitumor immune responses. Therefore, we next sought to determine whether PLX4720 therapy could alter the phenotype or function of tumor-infiltrating immune cells. We induced Braf^V600E/Pten melanomas and after 5 weeks the mice were treated with normal chow or that which contains PLX4720 (PLX diet) for another 3 weeks (Fig. 3A). As expected, PLX4720 treatment significantly decreased tumor weight (Fig. 3B). In agreement with recent studies, we also observed a 5-fold increase in the number of CD4 and CD8 T lymphocytes (Fig. 3C) infiltrating PLX4720-treated melanomas, but not the spleen, and this was confirmed by anti-CD3 immunohistochemical staining of tumor sections (Fig. 3D and Supplementary Fig. S3; refs. 18 and 19). In addition, the frequency of intratumoral FoxP3⁺ Treg CD4 T cells was reduced 3- to 4-fold after PLX4720 treatment, whereas no effect was observed in the spleen (Fig. 3E). These results suggested that PLX4720 affected the recruitment of Tregs into tumors or directly modulated inducible-Treg (iTreg) formation in the tumor microenvironment. Moreover, these data imply that PLX4720 preferentially promoted the accumulation of FoxP3⁻ CD4 T cells (non-Tregs) within the tumors, which may contain “helper” cells to boost antitumor responses.

Because we found that expression of effector cytokines from intratumoral CD4 T cells declined during tumor progression, we next tested whether PLX4720 treatment affected CD4 T-cell cytokine production. After PLX4720 therapy, a larger fraction of tumor-infiltrating CD4 T cells produced IFNγ (i.e., T_H1 cells; Fig. 3F). However, PLX4702 treatment did not affect the CD4 T-cell production of IL2 and TNFα. More notably, PLX4720 treatment also augmented the expression of CD40L on intratumoral CD4 T cells (Fig. 3G). Intriguingly, PLX4720 treatment robustly promoted PD1 expression on intratumoral CD4 T cells and the frequency of PD1⁺ CD4 T cells (Supplementary Fig. S4), supporting a similar observation in human melanoma following vemurafenib treatment (21). These results demonstrate that Braf^V600E inhibitors have a potent immunostimulatory activity in the Braf^V600E/Pten murine melanoma mouse and can greatly boost the effector T-cell:Treg ratio and T_H1 effector and helper functions within tumors.

Next, we investigated whether PLX4720 treatment also modulated the frequency or phenotype of tumor-infiltrating myeloid cells. First, we noted that PLX4720 therapy reduced the frequency of intratumoral CD11b⁺/Gr-1⁺ cells by 4- to 5-fold and slightly decreased the frequency of TAMs, but no in the TIDCs (Fig. 3H). PLX4720 therapy also enhanced the maturation status of both TAMs and TIDCs (Fig. 3I), suggesting that intratumoral APCs might possess a higher capability to activate and expand T cells and promote T_H1-polarized differentiation. Altogether, these findings demonstrated that PLX4720 treatment had potent immunostimulatory effects on the phenotype and function of innate and adaptive immune cells in the tumor microenvironment. PLX4720 treatment promoted the expression of IFNγ and CD40L on CD4 T cells, MHC, and costimulatory ligands on APCs and repressed accumulation of Tregs and CD11b⁺/Gr-1⁺ population, which collectively, may lead to enhanced antitumor immune responses.

Next, we investigated whether T cells contribute to PLX4720 antitumor effect. Tumors were induced in Braf^V600E/Pten mice and 5 weeks later the mice were treated with PLX4720 with or without TIB210 or GK1.5 mAbs for 15 days to deplete CD8 or CD4 T cells, respectively (Fig. 4A). The depleting antibodies reduced both splenic and intratumoral CD8 or CD4 T cells after 15 days of treatment (Supplementary Fig. S5). Surprisingly, the reduction in tumor growth by PLX4720 treatment did not depend on CD8 T cells, but was partially dependent on CD4 T cells (Fig. 4B–E). These results suggest that CD4 T cells play a more dominant role in the PLX4720-mediated antitumor response than CD8 T cells. Note, we also examined whether the elevated CD70 expression on APCs after PLX4720 therapy contributed to its ability to reverse tolerant CTLs and retard tumor growth (14, 15, 34), but found that blocking CD70 did not perturb the ability of PLX4720 to inhibit tumor progression in any detectable manner (Supplementary Fig. S6).

Because the antitumor response of PLX4720 treatment was compromised when CD4 T cells were depleted, it is possible that augmented effector and helper CD4 T-cell functions contribute to PLX4720-mediated immunostimulation of tumor microenvironment. CD40:CD40L signaling can augment immune surveillance of tumors by enhancing APC maturation, boosting macrophages' cytotoxicity, and elevating CTL proliferation and effector functions (13, 27–29, 35). To determine if increased CD40L expression on intratumoral CD4 T cells during PLX4720 treatment was functionally relevant, we blocked CD40L signaling during PLX4720 treatment using the anti-CD40L antibody (MR1; ref. 36). Tumors were induced in Braf^V600E/Pten mice and 5 weeks later the mice were treated with PLX4720 with or without anti-CD40L mAb (MR1) for 2 weeks. We found that blocking CD40:CD40L signaling strongly interfered with the antitumor effects of PLX4720 treatment because the Braf^V600E/Pten melanomas grew in the PLX diet+MR1 treated animals at rates similar to, but slightly less than untreated vehicle-injected control animals (Fig. 5A–C). MR1 treatment by itself did not have a significant effect on tumor growth in animals on normal chow diet. These results demonstrate that CD40:CD40L signaling was required for the suppression of tumor growth by PLX4720 therapy and suggest that host immunity contributes to the therapeutic effects of Braf^V600E inhibition on melanoma growth.

Further comparison revealed that the reduction in infiltrating Tregs observed during PLX4720 treatment was also dependent on CD40L signaling because greater percentages of Tregs were found in PLX+MR1–treated tumors as compared with those given PLX-alone (Fig. 5D). Similarly, CD40L signaling was important for the significant increase in total CD4 and CD8 T cells in the melanomas caused by PLX4720 treatment (Fig. 5E). In contrast, CD40L blockade did not affect the ability of PLX4720 treatment to reduce CD11b⁺/Gr-1⁺ population frequencies (Fig. 5F). Next, we sought to test if the enhanced maturation of intratumoral APCs observed during PLX4720 treatment was dependent on CD40:CD40L signaling. Indeed, CD40L blockade prevented PLX4720 therapy-induced elevation of MHC class I and CD70 on both TAMs and TIDCs (Fig. 5G). These experiments show that several of the notable immunostimulatory effects of PLX4720 on the microenvironment of melanoma depend on CD40L signaling, including the increased effector T-cell:Treg ratio and maturation status of APCs. These findings provide novel mechanistic insight into therapeutic effects of Braf inhibitors in melanoma and implicate host immunity as a critical part of the antitumor effects of these types of drugs.

In addition to CD40L, IFNγ is another antitumor immunologic factor that can promote MHC expression on both APCs and tumor cells, trigger tumor cell senescence and polarize M1-like macrophages (37, 38). Because the frequency of IFNγ-producing CD4 T cells was increased in the tumors after PLX4720 therapy, we next investigated if IFNγ itself was also involved in PLX4720-mediated antitumor responses by blocking IFNγ with the mAb XMG1.2 at the time of PLX4720 treatment. This showed that the therapeutic effects of PLX4720 were compromised in mice receiving IFNγ-neutralizing mAb because, as observed with blocking CD40L, the tumors in these mice grew at rates comparable to those left untreated (Fig. 6A–C). IFNγ-neutralizing antibody did not escalate tumor growth in mice receiving chow diet. We then examined which changes in the tumor microenvironment induced by PLX4720 therapy were IFNγ dependent. First, in contrast to anti-CD40L blockade, IFNγ blockade had minimal effect on altering intratumoral Treg frequency in either the normal- or PLX-diet fed mice (Fig. 6D). However, we found that blocking IFNγ suppressed the PLX4720-induced increase in infiltrating CD4 and CD8 T cells into the tumors, albeit the effects on CD4 T cells were insignificant (Fig. 6E). Although no notable changes in percentage of TAMs or TIDCs were observed when IFNγ was blocked during PLX4720 treatment (Supplementary Fig. S7), the frequency of CD11b⁺/Gr-1⁺ myeloid cells increased considerably in the tumors (Fig. 6F). This suggested that IFNγ-blockade affected CD11b⁺/Gr-1⁺ myeloid cells accumulation in tumors. We also examined the expression of MHCI and CD70 on TAMs and TIDCs and found that IFNγ blockade prevented PLX4720-induced upregulation of these proteins on APCs (Fig. 6G). Overall, these data showed that IFNγ was necessary for the PLX4720-mediated maturation of APCs and reduction of intratumotal CD11b⁺/Gr-1⁺ myeloid cells, which likely contributed to antitumor effects of PLX4720 in Braf^V600E/Pten melanomas.

The above findings reveal that the CD40:CD40L and IFNγ signaling pathways have potent antitumor activities during PLX4720 treatment, identifying new therapeutic opportunities to treat melanoma. Because agonistic anti-CD40 mAb treatment can evoke antitumor immune responses, we sought to evaluate the antitumor responses of agonistic anti-CD40 mAb in the Braf^V600E/Pten murine melanoma model. To this end, Braf^V600E/Pten melanomas were allowed to progress for 6 weeks, and then the mice were injected with control IgG or agonistic anti-CD40 antibody (FGK45; 250 μg/mouse) every 3 days for another 15 days. This experiment revealed that agonistic anti-CD40 mAb treatment could restrict tumor growth considerably (Fig. 7A–C). Importantly, mice treated with FGK45 mAb exhibited splenomegaly, yet no significant increases of intratumoral CD4 and CD8 T cells or CD11b⁺/Gr-1⁺ myeloid cells were observed (Supplementary Fig. S8A–S8D). However, the number of splenic and intratumoral Tregs was increased by FGK45 treatment (Supplementary Fig. S8E). Notably, agonistic anti-CD40 mAb treatment augmented the maturation status of both TAMs and TIDCs in Braf^V600E/Pten melanomas (Fig. 7D). We observed that neither CD45⁻ cells (including both tumor and stromal cells) directly isolated from Braf^V600E/Pten melanomas nor a Braf/Pten-derived melanoma cell line expressed CD40 by flow cytometry (Supplementary Fig. S9), lessening the possibility that FGK45 triggers antibody-dependent cell-mediated cytotoxicity (ADCC) of tumor cells. We next examined whether T cells are required for FGK45-dependent restriction of tumor growth, and surprisingly, T-cell depletion did not compromise the antitumor effects of FGK45 mAb treatment (Fig. 7E and F). Altogether, these results suggest that the apparent decline in CD40:CD40L signaling that occurs during Braf^V600E/Pten melanoma progression contributes to the formation of an immunosuppressive microenvironment, and augmentation of CD40 signaling via agonistic anti-CD40 mAb is a significant form of immunotherapy, that can operate independently of T cells, to reduce Braf^V600E/Pten melanoma growth.

Braf^V600E is a common driver-oncogene in melanoma and other cancers. Clinically available Braf^V600E inhibitors suppress tumor growth and it has been suggested that antitumor host immunity can be enhanced by these drugs (18–21). This study aimed to investigate the immune responses during tumor progression in an inducible Braf^V600E/Pten^lox murine melanoma model and identify how the Braf^V600E inhibitor PLX4720 altered the tumor microenvironment and infiltrating immune cells. We wanted to determine whether particular aspects of immune functions, cell types, or signaling pathways contributed to the therapeutic effects of Braf^V600E inhibition, as previously intimated by some studies in patients with melanoma (18–23, 39, 40). We found that the tumor microenvironment in Braf^V600E/Pten melanomas acquired multiple immunosuppressive features, including accumulation of Tregs, CD11b⁺/Gr-1⁺ myeloid cells, and immature APCs. Furthermore, intratumoral CD4 T cells lost their ability to exert effector (IFNγ) and helper (CD40L) functions. Surprisingly, PLX4720 therapy augmented the expression of CD40L and IFNγ on tumor-infiltrating CD4 T cells and impeded intratumoral accumulation of Tregs and CD11b⁺/Gr-1⁺ myeloid cells. To our knowledge, this is the first report that these particular CD4 T cell functions can be modulated by Braf^V600E inhibitor treatment. Moreover, we also found that treatment with an agonistic anti-CD40 mAb provided significant therapeutic benefits in suppressing melanoma growth and enhancing maturation of APCs in the Braf^V600E/Pten melanoma model. Altogether, these findings support the model that CD40L is critical in mounting protective antimelanoma immunity and have important implications in clinical trials involving immunotherapy. Possibly, combinational therapy with anti-CD40 agonists plus vemurafenib, anti-PD1, or anti-CTLA4 will enhance patient outcomes.

Vemurafenib and other Braf^V600E inhibitors were originally believed to affect cell proliferation and trigger apoptosis and senescence on tumor cells harboring Braf^V600E mutation. However, a number of studies revealed that Braf^V600E inhibitors might boost immunosurveillance of tumors in both patients and mice. Using melanoma cell line engraftment models in mice, several effects of Braf inhibition have been reported, such as increased tumor-infiltrating T lymphocytes, reduced intratumoral Tregs and CD11b⁺/Gr-1⁺ myeloid cells, and decreased CCL2, IL1α, and IL1β expression of tumor cells (18–23, 39, 40). Although these studies suggested that host immunity is critical to maximize the therapeutic efficacy of Braf^V600E inhibitors, tumors arising from engrafted cell lines are likely more immunogenic and most certainly do not fully recapitulate the microenvironment of tumors that arise endogenously in vivo. Therefore, elucidating which elements of the immune system are involved in the antitumor effects of Braf^V600E inhibitors and how Braf^V600E inhibitors relieve the immunosuppressive restraints imposed by the tumor microenvironment in a more pathophysiologically relevant murine model may enhance the development of antimelanoma immunotherapies. For this reason, we took the advantage of the inducible Braf^V600E/Pten melanoma model to investigate these important questions in a more physiologic manner. Our results showed that PLX4720 treatment significantly promoted tumor infiltration of T cells that depended on CD40:CD40L and IFNγ signaling. However, PLX4720 treatment has also been shown to decrease intratumoral lymphocyte frequencies in Braf^V600E/Pten melanoma model (23, 40) and the discrepancy between these studies might be because of different methods of tumor-infiltrating immune cell isolation and/or calculation of cell numbers (41). Our analysis went further and identified several previously unrecognized immunostimulatory effects of PLX4720 treatment on the immune microenvironment of tumors. Although adoptive CD4 T-cell transfer can help to establish antitumor immune responses (42, 43), the precise mechanisms are poorly understood and a recent report showed that CD4 T lymphocytes are required to re-establish antitumor immunity upon oncogene inactivation (44). In agreement with these findings, our results reveal that CD4 T cells contribute to PLX4720-induced antitumor responses and delineate underlying immune signaling pathways (e.g., IFNγ and CD40L) that break an immunosuppressive tumor microenvironment.

Although we found that PLX4720 therapy augmented the effector and helper functions of tumor-infiltrating CD4 T cells and diminished the accumulation of intratumoral Tregs in Braf^V600E/Pten melanomas, the underlying mechanism(s) by which PLX4720 induces these immunostimulatory properties remain unclear. In addition to inhibiting B-Raf kinase, some Braf^V600E inhibitors also paradoxically enhance C-Raf kinase activity by promoting heterodimerization between C-Raf and wild-type B-Raf (4). Although recent studies showed that PLX4720 and vemurafenib do not affect T lymphocyte functions and viability in a broad range of concentrations (4), this does not necessarily rule out that the effects we observed are independent C-Raf activity alteration. Moreover, the Braf^V600E mutation remodels the metabolic activities of cancer cells and Braf^V600E inhibitors can decrease glycolysis and glutaminolysis and elevate oxidative phosphorylation in melanomas (45–47). Given that nutrients, such as glutamine, arginine, and glucose, are critical for effector T-cell function and differentiation (48), it is possible that PLX4720-induced changes in tumor metabolism may indirectly lead to T_H1 or M1-like polarization in T cells and macrophages, respectively. Additional studies are needed to further elucidate the mechanisms by which PLX4720 treatment enhances immune activity and these could reveal previously unappreciated mechanisms of immunosuppression in the tumor microenvironment.

Melanoma cells have been shown to promote accumulation of Tregs and possibly CD11b⁺/Gr-1⁺ myeloid cells by secreting large amount of CCL2 and VEGF (18, 22), and accumulation of these immunomodulatory cells could dampen the activity and helper functions of T cells in tumors (8, 32, 33). Interestingly, our results demonstrated that CD40L and IFNγ blockade during PLX4720 treatment differentially affected the infiltration of intratumoral Tregs and CD11b⁺/Gr-1⁺ myeloid cells, respectively, indicating that the accumulation of these cells in tumors is likely governed by distinct pathways. Because CD11b⁺/Gr-1⁺ myeloid cells are immature myeloid cells and IFNγ can promote their differentiation into macrophages both in vitro and in vivo (38, 49), PLX4720 therapy might reduce the size of the CD11b⁺/Gr-1⁺ myeloid cells population by interfering with their recruitment or promoting their differentiation in an IFNγ-dependent manner. However, CD40L blockade can ameliorate autoimmune disease and rejection of cardiac allograft by inducing Treg formation and suppressing T- and B-cell activation and antibody production (36). Therefore, it is possible that the loss of CD40L signaling on T cells as tumors progress might facilitate Treg formation and impede T-cell activation within tumors. We also found that administration of agonistic anti-CD40 mAb alone could suppress tumor progression in this model of melanoma. Agonistic anti-CD40 antibody has been shown to be a new therapeutic option for a variety of cancers in preclinical studies and humanized anti-CD40 antibodies are under phase I trial (13, 27, 29). Activation of intratumoral macrophages and/or rejuvenation of exhausted or tolerized T cells might underlie the antitumor effects of this drug, but it is not clear if agonistic anti-CD40 antibody could potentiate the therapeutic efficacy of other immunotherapies. Because anti-CD40 treatment impedes Braf^V600E/Pten melanoma growth in a T-cell–independent manner, it is possible other immunotherapies that enhance TIL recruitment or function may act in synergy with anti-CD40 mAb treatment and provide alternative forms of treatment for Braf^V600E inhibitor-resistant melanomas.

Collectively, we found that PLX4720 treatment created a immunostimulatory tumor microenvironment, in part, by augmenting CD40:CD40L and IFNγ signaling. A future goal will be to evaluate the therapeutic efficacy of treatments that enhance CD40L and IFNγ signaling in combination with Braf^V600E inhibitors or other immunotherapies. After prolonged treatment, tumor cells acquire resistance to Braf^V600E inhibitors with additional mutations in MAPK pathways and other signaling cascades. However, tumor cells may gain resistance to immune attack by these additional mutations. For example, a recent study showed that activation of the MAPK pathway can elevate PDL1 expression in Braf^V600E inhibitor-resistant melanoma cells, which could dampen T-cell activity and antitumor immunity (50). Interestingly, our results showed that Braf^V600E inhibition augmented PD1 expression on infiltrating T cells, and a similar observation has been reported in humans (21). These findings raise the possibility that intratumoral CD4 T cells might become more sensitive to the PD1:PDL1 signaling pathways after vemurafenib treatment, which would support combining PD1 blockade with Braf^V600E inhibitor treatment to inhibit tumor growth or possibly delay resistance to Braf^V600E inhibitors. It would be an important issue for future studies to examine whether CD40:CD40L and IFNγ signaling would be diminished in Braf^V600E inhibitor-resistant melanoma and whether immunotherapies that provide these immune stimuli could be utilized to treat Braf^V600E inhibitor-resistant melanomas.

No potential conflicts of interest were disclosed.

Conception and design: P.-C. Ho, B. Srivastava, M.W. Bosenberg, S.M. Kaech

Development of methodology: P.-C. Ho, B. Srivastava, M.W. Bosenberg, S.M. Kaech

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P.-C. Ho, K.M. Meeth, Y.-C. Tsui, M.W. Bosenberg, S.M. Kaech

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): P.-C. Ho, M.W. Bosenberg, S.M. Kaech

Writing, review, and/or revision of the manuscript: P.-C. Ho, M.W. Bosenberg, S.M. Kaech

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S.M. Kaech

Study supervision: M.W. Bosenberg, S.M. Kaech

The authors thank all members of the Kaech and Bosenberg labs, Drs. K. Politi, and P. West for insightful discussions and experimental advice.

This work was supported in part by NIH R01AI074699, Yale Cancer Center (S.M. Kaech), Yale Spore in Skin Cancer Development Award (5 P50 CA121974), Melanoma Research Alliance Development Award (S.M. Kaech and M.W. Bosenberg), Howard Hughes Medical Institute (S.M. Kaech), Melanoma Research Foundation (M.W. Bosenberg), and the National Cancer Center (P-C. Ho).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.